HUNAN FANGSHENG PHARMACEUTICAL revenue for the last year amounted to 1.63 B CNY, the most of which — 384.55 M CNY — came from its highest performing source at the moment, Cardiovascular and Cerebrovascular Disease Medication, the year earlier bringing 448.95 M CNY. The greatest contribution to the revenue figure was made by China — last year it brought HUNAN FANGSHENG PHARMACEUTICAL 1.63 B CNY, and the year before that — 1.79 B CNY.